EVT for ischemic stroke patients with extensive signs of infarction presenting in the extended time window
Landmark stroke trials DAWN and DEFUSE 3 led to a paradigm shift in acute stroke care. The trials expanded the eligibility for endovascular thrombectomy (EVT) treatment in large vessel occlusion patients who presented within 6 to 24 hours from symptom onset. However, the trials included patients with small ischemic cores detected by CTP or diffusion-weighted imaging.